Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
Year: 2020
Type: article
Study design: Observational Study
Abstract: We examined if plasma phosphorylated tau is associated with neurodegeneration in Alzheimer's disease. We investigated 372 cognitively unimpaired participants, 554 mild cognitive impairment patients, and 141 Alzheimer's disease dementia patients. Tau phosphorylated at threonine 181, regional cortical thickness (using magnetic resonance imaging) and hypometabolism (using fluorodeoxyglucose positron emission tomography) were measured longitudinally. High plasma tau was associated with hypometabolism and cortical atrophy at baseline and over time, and longitudinally increased tau was associated with accelerated atrophy, but these associations were only observed in Aβ-positive participants. Plasma phosphorylated tau may identify and track processes linked to neurodegeneration in Alzheimer's disease.
DOI: 10.1002/acn3.51253
Authors: Oskar Hansson, Nicholas Cullen, Henrik Zetterberg, the Alzheimer’s Disease Neuroimaging Initiative, Kaj Blennow, Niklas Mattsson‐Carlgren
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,000
Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Roche, Biogen, University of Southern California, AbbVie, BioClinica, Novartis Pharmaceuticals Corporation, Takeda Pharmaceutical Company, Northern California Institute for Research and Education, Hjärnfonden, Knut och Alice Wallenbergs Stiftelse, Vetenskapsrådet, Fujirebio Europe, Sveriges Läkarförbund, National Institutes of Health, Genentech, Johnson and Johnson, GE Healthcare, European Research Council, National Institute on Aging, National Institute of Biomedical Imaging and Bioengineering
OpenAlex ID: W3108978978